MedTrace Logo

Effect of Direct AntiViral Drugs of Chronic HCV on eGFR in Assuit Universiry Hospital

NCT03965286 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2019-05-29

No results posted yet for this study

Summary

1. evaluation of glomerular filtration rate(eGFR)changes during HCV treatment with direct antiviral drugs according to 2018 guideline.
2. TO estimate the frequency of renal impairment by direct antiviral drugs By detection of any changes in e GFR.
3. Assessment The Renal safety during HCV treatment with direct antiviral drugs according to 2018 guideline.
4. To clarify the importance of laboratory and other modalities in detection and estimation of frequency of renal impairment by direct antiviral drugs according to 2018 guideline.

Conditions

  • Antiviral Drug

Interventions

DRUG

DAAs

Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) 12 weeks Daily simeprevir (150 mg) plus sofosbuvir (400 mg) 12 weeks Daily daclatasvir (60 mg) plus sofosbuvir (400 mg) 12 weeks Daily fixed-dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) with dasabuvir (600 mg) 12weeks

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Enas Alkareemy, MD · Assuit university hospital

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-06-01
Primary Completion
2020-06-30
Completion
2020-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03965286 on ClinicalTrials.gov